Posted by Michael Wonder on 05 Jan 2026
Altimmune receives FDA breakthrough therapy designation for pemvidutide in MASH
5 January 2026 - Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end of phase 2 meeting with US FDA.
Altimmune today announced the US FDA has granted breakthrough therapy designation for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dysfunction-associated steatohepatitis.
